Probable Donor-Derived Cytomegalovirus Disease After Keratolimbal Allograft Transplantation

Cornea. 2017 Aug;36(8):1006-1008. doi: 10.1097/ICO.0000000000001243.

Abstract

Purpose: To report a case of probable donor-derived cytomegalovirus (CMV) infection after keratolimbal allograft (KLAL) transplantation.

Methods: Observational case report.

Results: A 41-year-old man with a history of aniridic keratopathy and limbal stem cell deficiency underwent KLAL in his right eye. Preoperatively, he was negative for CMV IgG and IgM. Postoperatively, he was maintained on tacrolimus and mycophenolate mofetil for systemic immunosuppression; he was also on prophylactic valganciclovir (for CMV) and trimethoprim/sulfamethoxazole (for pneumocystis pneumonia) for 1 month. Approximately 5 weeks postoperatively, he developed a nonproductive cough, rhinorrhea, and dyspnea. His condition did not improve with oral azithromycin or levofloxacin. He developed worsening symptoms over the next 2 weeks despite therapy. The serum CMV polymerase chain reaction was positive, and he was readministered valganciclovir with subsequent resolution of symptoms.

Conclusions: We present the first case of CMV disease in a seronegative patient who received a presumed CMV-seropositive donor KLAL. Similar to solid organ transplantation, prophylactic and therapeutic management of CMV infection is necessary in the setting of systemic immunosuppression.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Allografts
  • Antiviral Agents / therapeutic use
  • Corneal Diseases / surgery*
  • Cytomegalovirus Infections / diagnosis
  • Cytomegalovirus Infections / drug therapy
  • Cytomegalovirus Infections / etiology*
  • Drug Therapy, Combination
  • Eye Infections, Viral / diagnosis
  • Eye Infections, Viral / drug therapy
  • Eye Infections, Viral / etiology*
  • Ganciclovir / analogs & derivatives
  • Ganciclovir / therapeutic use
  • Humans
  • Limbus Corneae / pathology
  • Male
  • Mycophenolic Acid / therapeutic use
  • Stem Cell Transplantation / adverse effects*
  • Tacrolimus / therapeutic use
  • Tissue Donors*
  • Valganciclovir

Substances

  • Antiviral Agents
  • Valganciclovir
  • Mycophenolic Acid
  • Ganciclovir
  • Tacrolimus